Table 2.
Characteristics of HCC patients between AKR1B10 high and low groups
| Variables | AKR1B10 expression level | P value | |
|---|---|---|---|
| Low (n = 180) | High (n = 181) | ||
| Gender, male (%) | 106 (58.9) | 138 (76.2) | < 0.001 |
| Age, median (IQR), years | 59.5 (20) | 62 (15) | 0.031 |
| BMI, kg/m2, n (%) | 0.132 | ||
| <18.5 | 14 (7.8) | 7 (3.9) | |
| 18.5~24.99 | 79 (43.9) | 73 (40.3) | |
| 25~29.99 | 36 (20.0) | 52 (28.9) | |
| >30 | 35 (19.4) | 32 (17.7) | |
| NA | 16 (8.9) | 17 (9.4) | |
| Race, n (%) | 0.36 | ||
| Asian | 77 (42.8) | 79 (43.6) | |
| White | 91 (50.6) | 85 (47.0) | |
| Black or African American | 7 (3.9) | 10 (5.5) | |
| American Indian or Alaska Native | 2 (1.1) | 0 (0) | |
| NA | 3 (1.6) | 7 (3.9) | |
| Tumor status, n (%) | 0.923 | ||
| With tumor | 53 (29.4) | 56 (30.9) | |
| Tumor free | 115 (63.9) | 112 (61.9) | |
| NA | 12 (6.7) | 13 (7.2) | |
| Family history of cancer, n (%) | 54 (30.0) | 78 (43.1) | 0.01 |
| Hepatocarcinoma risk factors*, n (%) | 0.006 | ||
| Hepatitis virus infection | 55 (30.6) | 56 (30.9) | |
| Alcohol consumption | 48 (26.7) | 67 (37.0) | |
| Non-alcoholic fatty liver disease | 6 (3.3) | 6 (3.3) | |
| No risk factors | 54 (30.0) | 32 (17.7) | |
| Other | 8 (4.4) | 10 (5.5) | |
| NA | 9 (5.0) | 10 (5.5) | |
| Neoplasm histologic grade, n (%) | 0.054 | ||
| G1 | 35 (19.4) | 18 (9.9) | |
| G2 | 76 (42.2) | 95 (52.5) | |
| G3 | 60 (33.3) | 61 (33.7) | |
| G4 | 6 (3.3) | 5 (2.8) | |
| NA | 3 (1.7) | 2 (1.1) | |
| AJCC stage, n (%) | 0.203 | ||
| I | 84 (46.7) | 83 (45.9) | |
| II | 35 (19.4) | 47 (26.0) | |
| III | 48 (26.7) | 33 (18.2) | |
| IV | 4 (2.2) | 3 (1.7) | |
| NA | 9 (5.0) | 15 (8.3) | |
| Vascular invasion, n (%) | 0.999 | ||
| Macro | 8 (4.4) | 8 (4.4) | |
| Micro | 44 (24.4) | 45 (24.9) | |
| None | 99 (55.0) | 101 (55.8) | |
| NA | 29 (16.1) | 27 (14.9) | |
| Child-pugh classification, n (%) | 0.525 | ||
| A | 101 (56.1) | 111 (61.3) | |
| B | 9 (5.0) | 12 (6.6) | |
| C | 1 (0.6) | 0 (0) | |
| NA | 69 (38.3) | 58 (32.0) | |
| AFP > 400ng/ml, n (%) | 39 (21.7) | 25 (13.8) | 0.051 |
| Platelet, median (IQR), ×103/mm3 | 204.5 (182) | 178 (136) | 0.066 |
| New tumor event after initial treatment, n (%) | 46 (25.6) | 47 (26.0) | 0.929 |
| Ishak fibrosis status, n (%) | 0.036 | ||
| No fibrosis | 44 (24.4) | 28 (15.5) | |
| Portal fibrosis | 10 (5.6) | 21 (11.6) | |
| Fibrous speta | 11 (6.1) | 17 (9.4) | |
| Nodular Formation/Incomplete Cirrhosis | 3 (1.7) | 6 (3.3) | |
| Cirrhosis | 30 (16.7) | 40 (22.1) | |
| NA | 82 (45.6) | 69 (38.1) | |
| Hepatic inflammation, n (%) | 0.033 | ||
| None | 69 (38.3) | 45 (24.9) | |
| Mild | 43 (23.9) | 54 (29.8) | |
| Severe | 7 (3.9) | 11 (6.1) | |
| NA | 61 (33.9) | 71 (39.2) | |
| Follow up, median (IQR), years | 0.378 (1.8) | 0.334 (1.3) | 0.453 |
IQR, interquartile range; BMI, body mass index; AJCC, American Joint Committee on Cancer; AFP, alpha-fetoprotein; NA, not available.
* Sum of all risk factors compared with no risk factors.